Terms: = Gastric cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Prognosis
38 results:
1. The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal cancers.
Lee MS; Kaseb AO; Pant S
Clin Cancer Res; 2023 Sep; 29(17):3267-3274. PubMed ID: 37092904
[TBL] [Abstract] [Full Text] [Related]
2. fgfr2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract.
Albin J; Fahrig L; Siemanowski J; Rehkaemper J; Gebauer F; Zander T; Buettner R; Bruns CJ; Schroeder W; Alakus H; Hieggelke L; Quaas A
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5289-5300. PubMed ID: 36416959
[TBL] [Abstract] [Full Text] [Related]
3. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.
Cheng L; Wang Y; Qiu L; Chang Y; Lu H; Liu C; Zhang B; Zhou Y; Bai H; Xiong L; Zhong H; Nie W; Han B
J Transl Med; 2022 May; 20(1):247. PubMed ID: 35642038
[TBL] [Abstract] [Full Text] [Related]
4. Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer.
Kim H; Heo YJ; Cho YA; Kang SY; Ahn S; Kim K-
Clin Transl Oncol; 2022 Mar; 24(3):556-567. PubMed ID: 34767183
[TBL] [Abstract] [Full Text] [Related]
5. The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration.
Ooki A; Yamaguchi K
Gastric Cancer; 2021 Nov; 24(6):1169-1183. PubMed ID: 34398359
[TBL] [Abstract] [Full Text] [Related]
6. Circulating Tumor DNA Analysis Detects
Jogo T; Nakamura Y; Shitara K; Bando H; Yasui H; Esaki T; Terazawa T; Satoh T; Shinozaki E; Nishina T; Sunakawa Y; Komatsu Y; Hara H; Oki E; Matsuhashi N; Ohta T; Kato T; Ohtsubo K; Kawakami T; Okano N; Yamamoto Y; Yamada T; Tsuji A; Odegaard JI; Taniguchi H; Doi T; Fujii S; Yoshino T
Clin Cancer Res; 2021 Oct; 27(20):5619-5627. PubMed ID: 34376535
[TBL] [Abstract] [Full Text] [Related]
7. cancer-related fgfr2 overexpression and gene amplification in Japanese patients with gastric cancer.
Minashi K; Yamada T; Hosaka H; Amagai K; Shimizu Y; Kiyozaki H; Sato M; Soeda A; Endo S; Ishida H; Kamoshida T; Sakai Y; Shitara K
Jpn J Clin Oncol; 2021 Oct; 51(10):1523-1533. PubMed ID: 34258618
[TBL] [Abstract] [Full Text] [Related]
8. CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration.
Shi M; Gu Y; Jin K; Fang H; Chen Y; Cao Y; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Qin J; Li R; Zhang H; Zhang W
Cancer Immunol Immunother; 2021 Jul; 70(7):1831-1840. PubMed ID: 33389016
[TBL] [Abstract] [Full Text] [Related]
9. Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric cancers.
Chaudhary SP; Kwak EL; Hwang KL; Lennerz JK; Corcoran RB; Heist RS; Russo AL; Parikh A; Borger DR; Blaszkowsky LS; Faris JE; Murphy JE; Azzoli CG; Roeland EJ; Goyal L; Allen J; Mullen JT; Ryan DP; Iafrate AJ; Klempner SJ; Clark JW; Hong TS
Oncologist; 2020 Nov; 25(11):e1691-e1700. PubMed ID: 32820577
[TBL] [Abstract] [Full Text] [Related]
10. A comparative study of RTK gene status between primary tumors, lymph-node metastases, and Krukenberg tumors.
Wang B; Tang Q; Xu L; Teng X; Ding W; Ren G; Wang X
Mod Pathol; 2021 Jan; 34(1):42-50. PubMed ID: 32732929
[TBL] [Abstract] [Full Text] [Related]
11. High-level fgfr2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers.
Hur JY; Chao J; Kim K; Kim ST; Kim KM; Klempner SJ; Lee J
Pathol Res Pract; 2020 Apr; 216(4):152878. PubMed ID: 32089408
[TBL] [Abstract] [Full Text] [Related]
12. Bridging genomics and phenomics of gastric carcinoma.
Cho J; Ahn S; Son DS; Kim NK; Lee KW; Kim S; Lee J; Park SH; Park JO; Kang WK; An JY; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kim KM
Int J Cancer; 2019 Nov; 145(9):2407-2417. PubMed ID: 30801717
[TBL] [Abstract] [Full Text] [Related]
13. Establishment of a New Scirrhous gastric cancer Cell Line with fgfr2 Overexpression, OCUM-14.
Okuno T; Yashiro M; Masuda G; Togano S; Kuroda K; Miki Y; Hirakawa K; Ohsawa M; Wanibuchi H; Ohira M
Ann Surg Oncol; 2019 Apr; 26(4):1093-1102. PubMed ID: 30652228
[TBL] [Abstract] [Full Text] [Related]
14. fgfr2 Promotes gastric cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway.
Huang T; Liu D; Wang Y; Li P; Sun L; Xiong H; Dai Y; Zou M; Yuan X; Qiu H
Cell Physiol Biochem; 2018; 50(4):1332-1345. PubMed ID: 30355943
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic role of fibroblast growth factor receptor 2 in human solid tumors: A systematic review and meta-analysis.
Liu G; Xiong D; Xiao R; Huang Z
Tumour Biol; 2017 Jun; 39(6):1010428317707424. PubMed ID: 28618942
[TBL] [Abstract] [Full Text] [Related]
16. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.
Du J; Wu X; Tong X; Wang X; Wei J; Yang Y; Chang Z; Mao Y; Shao YW; Liu B
Oncotarget; 2017 Apr; 8(16):26281-26287. PubMed ID: 28460431
[TBL] [Abstract] [Full Text] [Related]
17. Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?
Hierro C; Alsina M; Sánchez M; Serra V; Rodon J; Tabernero J
Ann Oncol; 2017 Jun; 28(6):1207-1216. PubMed ID: 28327938
[TBL] [Abstract] [Full Text] [Related]
18. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and fgfr2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract] [Full Text] [Related]
19. Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing fgfr2-induced ERK phosphorylation and cancer progression.
Xu Y; Yang X; Li Z; Li S; Guo S; Ismail S; Liu H; Huang Z; Zhang Z; Chen Y; Sun Q
Oncotarget; 2017 Jan; 8(3):4888-4900. PubMed ID: 28002800
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Seo S; Park SJ; Ryu MH; Park SR; Ryoo BY; Park YS; Na YS; Lee CW; Lee JK; Kang YK
Oncotarget; 2017 May; 8(20):33844-33854. PubMed ID: 27802183
[TBL] [Abstract] [Full Text] [Related]
[Next]